Drugs / ASKB589
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05632939 | Feb 2023 → Oct 2025 overdue | gastric cancer, gastroesophageal cancer | AskGene Pharma, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04632108 | Jan 2021 → Oct 2025 overdue | cancer | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06206733 | Jan 2024 → Dec 2026 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | AskGene Pharma, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-27 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Results 2025 ESMO | Latest Research Results of ASKB589 (CLDN18.2 mAb) Triple Combination Therapy Announced ask-pharm.com ↗
The data disclosed at ESMO further confirm the significant and durable antitumor activity of the ASKB589 triple-combination report, for the first time, OS benefit in patients with previously untreated advanced G/GEJ adenocarcinoma expressing CLDN18.2 at medium-to-high levels: |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-27 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 2025 ESMO | Latest Research Results of ASKB589 (CLDN18.2 mAb) Triple Combination Therapy Announced ask-pharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASKB589 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05632939 ↗ |
| Route | Intravenous | “ASKB589 is administered intravenously” NCT05632939 ↗ |